Adipose Stem Cell Market Current Situation & Growth Forecast to 2026: PromoCell, Cellerant Therapeutics, ScienCell Research Laboratories, BioTime …

Infinity Business Insights has announced the addition of new research analysis on the global Adipose Stem Cell Market to its vast library, Offering Insights for Adipose Stem Cell Industry Over the Project Time Frame of 2021-2026. The market is anticipated to rise at a considerable rate during the forecast period. In recent years, the market was growing at a steady rate, and with the rising adoption of strategies by key players; the market is expected to rise over the projected horizon.

Read more
NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy – Business Wire

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics. Recent breakthroughs in stem cell therapy, regenerative medicine, and CRISPR engineering have advanced the development of promising new treatments for debilitating diseases across a broad range of research areas, including neurological and cardiovascular disease, vision loss, and certain types of cancers.

Read more
Stem Cell manufacturing Market All-Inclusive Research Report (20212027) : Includes Impact of COVID-19 The Manomet Current – The Manomet Current

Data Bridge Market Research has recently added a concise research on theGlobal Stem Cell Manufacturing Market to depict valuable insights related to significant market trends driving the industry. The report features analysis based on key opportunities and challenges confronted by market leaders while highlighting their competitive setting and corporate strategies for the estimated timeline. The development plans, market risks, opportunities and development threats are explained in detail.

Read more
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene…

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ --Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, andAruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant's investigational lentiviral gene therapy for sickle cell disease (SCD).

Read more